Indivior - M&A Summary and Business Overview

Life ScienceCompany

Indivior M&A Summary

Indivior has acquired 1 company, including 1 in the last 5 years.

Indivior’s largest acquisition to date was in 2022, when it acquired Opiant Pharmaceuticals for $145M. Indivior has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).

Indivior Business Overview

Where is Indivior headquartered?

Indivior is headquartered in North Chesterfield, Virginia.

What is Indivior’s revenue?

Indivior disclosed revenue of 1,093M USD for 2023 and 901M USD for 2022.

How many employees does Indivior have?

Indivior has 1,000 employees.

What sector is Indivior in?

Indivior is a life science company.

M&A Summary

  • M&A Total Activity1
    • M&A Buy Activity1
  • Total Sectors Invested 1
  • Total Countries Invested 1
  • M&A Advisors 2

Indivior

Indivior PLC

10710 Midlothian Turnpike,
North Chesterfield, Virginia 23235
United States,
(804) 379-1090
www.Indivior.com

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy, health policy and evidence-based best practice models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline “Focus on you” makes the company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its robust, global opioid dependence portfolio featuring SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII), SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX® (buprenorphine) Sublingual Tablet, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic diseases of addiction – including opiate overdose, alcohol use disorders and cocaine intoxication. It also is pursuing novel product candidates in related mental health disorders such as schizophrenia. Indivior is based in North Chesterfield, Virginia.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.2/yr) # - - - 1 - - 1
vol $145M $145M
Sell (0.0/yr) # - - - - - - 0
  1

Most Recent M&A

Company Date Value Type
Opiant Pharmaceuticals, Inc. 2022-11-14 145M USD Add-on Acquisition
Santa Monica, California · www.opiant.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 1 (100%) 145M (100%) - -
Total 1 $145M - -

By Geo

State/Country Buy Value Sell Value
United States 1 145M - -
  California 1 145M - -
Total 1 $145M - -

Top M&A Advisors

Financial Deals
Centerview Partners
1
Legal Deals
Covington & Burling
1

Deal Values

buy # Total
$100M to $1B 1 $145M
TOTAL $145M
Largest Opiant Pharmaceuticals, Inc.
$145M (2022-11-14)

 Subscribe to unlock this and 206,153
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.